◆ 会议时间：2024年8月21-25日
◆ 会议地点：新加坡(Singapore)
◆ 会议简介
2024年第26届亚太风湿病协会联盟(APLAR)大会将于2024年8月21-25日在新加坡举行，会议由亚太风湿病学会联盟(APLAR)组织。亚太风湿病学大会（APLAR年会）是交流风湿病学领域前沿科学研究和临床信息的重要活动，会议为风湿病学家、内科医生、骨科医生、临床免疫学家、物理学家、物理和职业治疗师、儿科医生和研究人员提供了一个最佳的讨论该地区肌肉骨骼疾病等方面信息的平台。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)
亚太风湿病协会联盟（APLAR）于1963年在悉尼成立，原是澳大利亚、印度、日本和新西兰四个国家成立的SEAPAL（东南亚和太平洋地区抗风湿病联盟），随着不断的发展，后改名为亚太风湿病协会联盟（APLAR）。APLAR隶属于ILAR（国际风湿病协会联合会）。APLAR由亚洲太平洋地区各国的风湿病学学会组成，现包括30个国家风湿病协会成员，APLAR所覆盖的地理区域从大洋洲的新西兰一直延伸到中东的约旦，通过会员协会代表25,000多名风湿病学家，是亚太地区最具影响力的风湿病学专业机构之一。APLAR致力于在亚太地区宣宣传和促进风湿病学科的发展工作。APLAR出版“APLAR风湿病学”杂志，并每年组织亚太地区最具影响力的风湿病学大会。
APLAR 2024
26th Asia-Pacific League of Associations for Rheumatology Congress
Date: August 21-25, 2024
Venue: Suntec, Singapore
Organized by:
Asia-Pacific League of Associations for Rheumatology (APLAR)
摘要征文投稿：
Submissions close: 29 April 2024
Notifications sent: Late May 2024
点此提交摘要>>>Submit Abstract>>>
Abstract submission guidelines
Outlined below are the guidelines that must be followed when submitting your work to APLAR 2024.
- All submissions must be in English. English is the official congress language and all presentations must also be in English
- Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
- Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
- Only standard abbreviations may be used within submissions
- References are not required for submissions
- The abstract title, section headings and references are not included in the overall word count
- Abstracts should follow the following format
- Background/Purpose: background or statement of purpose
- Methods: methods, materials and analytical procedure used
- Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
- Conclusion: conclusions reached
- Tables, graphs and images are permitted within submissions (maximum 2)
- What is an encore presentation?
An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event.
- Does APLAR 2024 accept encore presentations?
- Yes we do accept encore presentations
- Encore presentations are permitted as long as work has been presented after APLAR 2023 (7 – 11 December 2023)
- Encore presentations are permitted as long as work has not previously been published prior to submission
- Encore submissions are required to disclose the name and date of the event where it has been presented
- Original abstracts are strongly recommended
Abstract submission topics
- Advances in pain management
- Allied health: alternative medicine
- Allied health: case report
- Allied health: COVID-19
- Allied health: nursing
- Allied health: physiotherapy
- Allied health: psychological intervention and miscellaneous forms of care
- Antiphospholipid syndrome
- Autoinflammatory diseases
- Basic science related to rheumatic diseases
- Behcet’s disease and miscellaneous rheumatic conditions
- Big data
- Case report
- Clinical immunology related to rheumatic diseases
- COVID-19
- Crystal-induced diseases
- Epidemiology, COPCORD, health care system and pharmacoeconomics
- Fibromyalgia
- Genetics
- IgG4-related disease
- Imaging techniques and diagnosis
- Infection-related rheumatic diseases
- Medical technologies and innovation (including AI)
- Metabolic bone diseases
- Osteoarthritis
- Paediatric rheumatology
- Precision medicine
- Psoriatic arthritis
- Rehabilitation for rheumatic diseases
- Rheumatoid arthritis anti-TNF therapy
- Rheumatoid arthritis bDMARDs
- Rheumatoid arthritis clinical aspects and co-morbidity
- Rheumatoid arthritis csDMARDs
- Rheumatoid arthritis non biological treatment
- Rheumatoid arthritis non-TNF biological therapies
- Rheumatoid arthritis tsDMARDs
- Scleroderma, myositis and related syndromes
- Sjogren syndrome
- Soft tissue rheumatism
- Spondylarthropathies biological and non-biological therapies
- Spondylarthropathies clinical aspects and co-morbidity
- Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications
- Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies
- Systemic vasculitis related to rheumatic diseases
- Telemedicine
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
